Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation

PLoS ONE - United States
doi 10.1371/journal.pone.0160277
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Natalizumab Treatment in Multiple Sclerosis

Clinical Neurology
Neurology
2015English

Natalizumab Therapy for Highly Active Pediatric Multiple Sclerosis

JAMA Neurology
Neurology
2013English

Pathogenic T Cell Cytokines in Multiple Sclerosis

Journal of Experimental Medicine
MedicineAllergyImmunology
2019English

Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management
Chemical HealthPharmacologySafetyMedicineToxicologySafety ResearchPharmaceutics
2007English

Alemtuzumab Following Natalizumab in Highly Active Paediatric-Onset Multiple Sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical
2019English

Predictors for Multiple Sclerosis Relapses After Switching From Natalizumab to Fingolimod

Multiple Sclerosis
Neurology
2014English

Natalizumab Versus Fingolimod and Dimethyl Fumarate in Multiple Sclerosis Treatment

Annals of Clinical and Translational Neurology
NeuroscienceNeurology
2018English

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

New England Journal of Medicine
Medicine
2006English

Increased CD8+ T Cell Responses to Apoptotic T Cell-Associated Antigens in Multiple Sclerosis

Journal of Neuroinflammation
Molecular NeuroscienceNeurologyImmunologyCellularNeuroscience
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy